2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.02 Pretreatment Plasma sCD14 as a Prognostic Indicator in aNSLC Patients Undergoing Immunotherapy

Pdf Summary

The study investigates the prognostic potential of secretory CD14 (sCD14) in plasma for patients with advanced non-small-cell lung cancer (aNSCLC) undergoing immunotherapy. This research builds on previous findings where CD14CD16-HLA-DRhi monocytes were found to be significant prognostic indicators in metastatic melanoma patients receiving immune-checkpoint blockade. However, the role of sCD14 in aNSCLC had been unexplored until now.<br /><br />Researchers collected 149 pretreatment plasma samples from aNSCLC patients treated with anti-PD1 therapy at the Cancer Hospital, Chinese Academy of Medical Sciences, between 2016 and 2023. Through flow cytometry, they screened 41 cytokines to identify markers distinguishing between patients with durable clinical benefit (DCB) and non-durable clinical benefit (NDB). An independent cohort validated these cytokines, and the prognostic value of sCD14 was confirmed with bulk-RNA sequencing.<br /><br />Eight predictive cytokines, including CD14, were identified for their baseline predictive efficacy based on their AUC values. CD14 expression was further validated in bulk-RNA sequencing datasets, showing significant prognostic value. A comparative analysis showed that CD14 is enriched in monocytes, especially those with elevated PD-L1 expression and enrichment in significant signaling pathways like INFLAMMATORY_RESPONSE and IL6_JAK_STAT3_SIGNALING.<br /><br />The study concludes that sCD14 could serve as a valuable biomarker for monitoring aNSCLC patients on immunotherapy, providing prognostic insights into progression-free survival. Higher baseline levels of sCD14 correlated with superior survival outcomes. Additionally, the enhanced PD-L1 expression in CD14 monocytes suggests a potential role in modulating immunotherapy responses, highlighting the relevance of sCD14 in clinical applications for aNSCLC management.

Asset Subtitle

Liyuan Dai

Meta Tag

Speaker Liyuan Dai

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

sCD14

aNSCLC

immunotherapy

prognostic biomarker

PD-L1 expression

monocytes

cytokines

progression-free survival

bulk-RNA sequencing

immune-checkpoint blockade